News & Events

Recent News & Events

Apr 04, 2016
National Oral Cancer Awareness Survey Reveals Shocking Statistics

FORT LAUDERDALE, Fla. A recent national consumer survey released by Vigilant Biosciences revealed that among U.S. adults, the majority knows very little or nothing at all about oral cancer (58 percent) and only 37 percent reported being screened for oral cancer at their last dental check-up.

Jun 10, 2016
Oral Rinse Test Picks Up Early-Stage Oral Cancer

An inexpensive oral rinse test has been shown to distinguish head and neck cancer patients from people who are at high risk for the disease, and offers hope that the diagnosis of oral cancer could be made at a much earlier stage than it is currently.

Media Coverage
The OncAlert oral cancer product line from Vigilant Biosciences Inc, Fort Lauderdale, Fla, is now available in select markets. The company’s OncAlert oral cancer product line includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting the CE mark. The tests are based on technology that accurately measures […]
For Matthew Kim, the idea for his company came when he was taking his mother to doctor visits for her cancer treatments. She was on her third battle with oral cancer, while Kim had a consulting firm and the fortunate flexibility to take her to her chemotherapy, radiation and rehabilitation.          
When Matthew Kim, founder and CEO of Vigilant Biosciences in Fort Lauderdale started his company in 2011, he quickly found funding to be a serious challenge. Ultimately, he persuaded an out-of-state investor to help, but in his most recent financing round, he received support from venVelo, an early-stage angel fund in Orlando, the Florida Institute […]
The Mistake: I fell in love with a technology before understanding the impact or value the technology can have in the real world. In my prior medical startup, I created a drug delivery platform which had a very novel way of delivering medication to the lungs systemically. I licensed and started the company and raised […]
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity, and pharynx) cancer each year worldwide, with mortality rates reaching up to 292,000 deaths each year.1 In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting […]
Florida’s startup and expanding companies so far this year have raised $1 billion in venture capital and angel investments, more than double 2015’s total of $459.89 million, according to a MoneyTree Report released Friday. While on track for the best year since 2000, Florida companies’ venture capital during the third quarter is less than 1 […]
Vigilant Biosciences, a developer of solutions that aid in the early detection and intervention of cancer, has received a Phase I Small Business Innovation Research grant of $219,454 from the National Institute of Dental and Craniofacial Research. The 15-month grant will fund research by Vigilant Biosciences to develop a diagnostic test that utilizes optical imaging […]
Head and neck cancer is a growing challenge with more than 650,000 new cases and more than 360,000 deaths worldwide each year. Historically, the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. More than 40 percent of those diagnosed with oral cancer die within five years.
Vigilant Biosciences, an oral cancer testing company, announced that it has raised a total of $10.5 million in Series B financing. The second phase of the Series B round brought in $5 million and investors in this phase included White Owl Capital Partners, venVelo and others. Investment in this round also came from a group of private […]
View More
Press Releases
Survey conducted by Vigilant Biosciences, Head and Neck Cancer Alliance, Oral Cancer Foundation and Support for People with Oral and Head and Neck Cancer reveals low awareness, misconceptions and desire for more information on oral cancer
Vigilant Biosciences, Inc. today announced the acceptance of five abstracts regarding data related to studies conducted by the Company to better understand the performance characteristics of a combined salivary CD44 and total protein assay as an aid in the diagnosis of head and neck squamous cell carcinoma (HNSCC).The studies, along with others, helped provide direction for […]
Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, will showcase its OncAlert® Oral Cancer product line in Hall 5.1, Stand: D069 at the 37th International Dental Show (IDS), the world’s leading tradeshow for the dental industry, being held March 21-25, 2017 in Cologne, […]
Matthew H.J. Kim, Founder, Chairman and CEO at Vigilant Biosciences, will present a poster on the study, “Multivariate oral rinse models predict Head and Neck squamous cell carcinoma (HNSCC),” at the 6th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO), from March 16-18, 2017, in Barcelona, Spain.      
Matthew H.J. Kim, Founder, Chairman and Chief Executive Officer at Vigilant Biosciences, will present at two upcoming conferences in San Francisco: the BioLink 2017 China Healthcare Industry Investment and Licensing Conference, taking place January 8, 2017 at the San Francisco Hilton Airport Hotel, and Medtech Showcase 2017 (at Biotech Showcase™), taking place at the Parc 55 San Francisco, January 10 – 11, […]
Vigilant Biosciences today announced exclusive multi-year distribution agreement for sales and marketing of its OncAlert® Oral Cancer product line in Spain, Portugal and Germany. The Company made the announcement in conjunction with the MEDICA Trade Fair, where the Company is showcasing its OncAlert Oral Cancer product line in Hall 16, booth #D04.      
Company to deliver oral presentation of data related to studies conducted to better understand the relationship between CD44, EGFR and p16 expression in oral cavity and oropharyngeal cancers, and whether particular patterns of CD44, EGFR and p16 staining are associated with overall and progression-free survival.
The study, titled, “Multivariate models which include oral rinse CD44 and total protein levels combined with clinical variables accurately predicts head and neck squamous cell carcinoma,” was based on previous proof-of-concept studies conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, which demonstrated the ability to identify the presence of the […]
Company to give presentation of data related to proof-of-concept studies by Sylvester Comprehensive Cancer Center (“Sylvester”) at the University of Miami Miller School of Medicine, titled CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients at American Head and Neck Society (AHNS) 9th International Conference on Head and Neck Cancer.
View More
April 1 – 5, 2017
April 4 – 8, 2017
April 26 – 30, 2017
April 28 – May 3, 2017
June 22 – 24, 2017
July 30 – August 3, 2017
August 29 – September 1, 2017
October 9 – 14, 2017
View More


Jennifer Moritz
Zer0 to 5ive


Paula Schwartz
Rx Communications Group, LLC